Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares traded down 5.5% on Monday . The stock traded as low as $69.2750 and last traded at $70.06. 628,948 shares traded hands during mid-day trading, an increase of 232% from the average session volume of 189,291 shares. The stock had previously closed at $74.14.
Gemini Therapeutics Price Performance
The company’s fifty day simple moving average is $77.77 and its 200-day simple moving average is $70.89. The firm has a market capitalization of $3.04 billion, a PE ratio of -70.06 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics was a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company’s research centered primarily on ophthalmology, with an emphasis on therapies for retinal and complement-related disorders.
Its lead investigational product was GEM103, a recombinant form of human complement factor H. Gemini evaluated GEM103 as a potential treatment for geographic atrophy, an advanced form of dry age-related macular degeneration associated with degeneration of the retina.
Featured Stories
- Five stocks we like better than Gemini Therapeutics
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
